Under the terms of the agreement with GSK, Anacor retains responsibility for the development of AN3365, and other boron-containing, little molecules through scientific proof of concept, at which point GSK will have an exclusive option to license each compound for further development and commercialization on a worldwide basis. Contingent on attaining particular milestones, Anacor is eligible to receive discovery, development, regulatory and industrial milestones ranging up to $252 million and $331 million for every product candidate. If GlaxoSmithKline exercises its choice at the proof concept stage, Anacor will receive tiered dual digit royalties, which are dependent on sales achieved.. Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study Anacor Pharmaceuticals today announced that it has dosed the first patient in a Phase I clinical study for AN3365, a novel boron-based, small-molecule medication candidate in advancement for the treating hospital infections due to Gram-negative bacteria.As of Tuesday, only 12.8 million were available. In a sign of how the virus is spreading rapidly, education officials said 198 schools in 15 says were closed Wednesday because of swine flu, with more than 65,000 students affected. That was up from 88 school closings the day before. Right now, the vaccine is certainly in a competition against the virus, and the virus is winning, Osterholm said. The government now expectations to have about 50 million dosages out by mid-November and 150 million in December, Dr. Nicole Lurie, assistant health and human providers secretary for preparedness, told The Associated Press on Wednesday. By the finish of November, I believe we’re going to be pretty much back on track, she said.